PDS Biotechnology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 25
- Market Cap
- $114.8M
- Website
- http://www.pdsbiotech.com
- Introduction
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its product, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.
PDS Biotechnology's Versamune® HPV Shows Promise in Phase 2 Trial
Suspicious activity violating Terms of Use detected on TipRanks account, including excessive page views or use of scraping tools. Account usually reactivates within 24 hours; contact support if still disabled.
PDS Biotechnology: Continuing The Holding Pattern (NASDAQ:PDSB)
PhD biochemist educates on science behind biotech investments, emphasizing due diligence to avoid pitfalls. No stock positions or compensation from mentioned companies.
PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial
PDS Biotech announces updated VERSATILE-002 Phase 2 trial results: Median Overall Survival of 30 months, Objective Response Rate of 36%, and Disease Control Rate of 77% for Versamune® HPV + KEYTRUDA® in HPV16-positive recurrent/metastatic HNSCC. Plans to initiate VERSATILE-003 Phase 3 trial this year.
PDS Biotechnology announces updates data from VERSATILE-002 trial
PDS Biotechnology presented updated VERSATILE-002 trial data on Versamune HPV + KEYTRUDA for HPV16+ recurrent/metastatic HNSCC at ESMO 2024. Median Overall Survival was 30 months (95% CI 19.7), compared to 12-18 months for pembrolizumab. Objective Response Rate was 36% vs. 19-25%, Disease Control Rate was 77%, and 21% had deep tumor responses. 9% had complete responses, and 9 patients experienced Grade ≥3 treatment-related adverse events.
© Copyright 2025. All Rights Reserved by MedPath